AstraZeneca PLC Appoints Andreas Rummelt as a Non-Executive Director, Effective 1 August 2021
July 22, 2021 at 02:00 am EDT
AstraZeneca PLC announced that the Board has appointed Andreas Rummelt as a Non-Executive Director, following the completion of its acquisition of Alexion Pharmaceuticals Inc. Dr. Rummelt has been a member of the Board of Alexion since 2010. His effective date of appointment to AstraZeneca's Board is 1 August 2021, the same as that of AstraZeneca's new Executive Director and Chief Financial Officer, Dr. Aradhana Sarin (formerly Executive Vice-President, Chief Financial Officer of Alexion), as previously announced on 4 June 2021. Dr. Andreas Rummelt has more than 20 years' experience in executive management positions in the pharmaceutical industry. His international career has focused on technical research and development, manufacturing and quality, as well as a period leading a generics business as Chief Executive Officer. He is now Chairman and Managing Partner of InterPharmaLink AG.